Vaxcyte CAO Elvia Cowan exercises 3,000 options

The stock-option entry reports 71,068 securities following the transaction.

Available on EDGAR 11/04/2026 - 04:52 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:52 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

At Vaxcyte, Inc., SVP, Finance & CAO Elvia Cowan exercised options to acquire 3,000 shares of common stock at $25.92 on November 2, 2026. On that date, she sold 2,414 shares at a weighted-average price of $60.765 and 586 shares at a weighted-average price of $61.547. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025; the option was fully vested and exercisable.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,000 shares ($105K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Cowan Elvia

Role SVP, Finance & CAO

Sold 3,000 shs ($183K)

Approx. gross sale proceeds $183K

Approx. exercise cost $78K

Approx. pre-tax spread $105K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^F4	3,000	$0.00	$0.00
Exercise	Common Stock	3,000	$25.92	$78K
Sale	Common Stock ^{F1, F2}	2,414	$60.765	$147K
Sale	Common Stock ^{F1, F3}	586	$61.547	$36K

Holdings After Transaction: Stock Option (right to buy) — 71,068 contracts (Direct); Common Stock — 27,860 shares (Direct)

Footnotes (4)

F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $60.345 to $61.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $61.425 to $61.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4. Stock Option is fully vested and exercisable.

Key Figures

Shares acquired through option exercise: 3,000 shares Exercise price: $25.92 per share Shares sold: 2,414 shares at $60.765 per share +2 more

5 metrics

Shares acquired through option exercise 3,000 shares Common stock acquired November 2, 2026

Exercise price $25.92 per share Option exercise on November 2, 2026

Shares sold 2,414 shares at $60.765 per share Weighted-average sale price on November 2, 2026

Shares sold 586 shares at $61.547 per share Weighted-average sale price on November 2, 2026

Securities following option transaction 71,068 securities Stock-option entry following the November 2, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted-average price, fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

fully vested and exercisable financial

"Stock Option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCVX shares did Elvia Cowan sell?

Elvia Cowan sold 2,414 shares at a weighted-average price of $60.765 and 586 shares at a weighted-average price of $61.547 on November 2, 2026. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

What PCVX stock options did Elvia Cowan exercise?

Elvia Cowan exercised options to acquire 3,000 shares of common stock at $25.92 on November 2, 2026. The stock-option entry reported 71,068 securities following the transaction, and the option was fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last)

(First)

(Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/02/2026		M		3,000	A	$25.92	30,860	D
Common Stock	11/02/2026		S⁽¹⁾		2,414	D	$60.765⁽²⁾	28,446	D
Common Stock	11/02/2026		S⁽¹⁾		586	D	$61.547⁽³⁾	27,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$25.92	11/02/2026		M			3,000	⁽⁴⁾	08/08/2032	Common Stock	3,000	$0	71,068	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

2. The price reported is a weighted-average price. The shares were sold at prices ranging from $60.345 to $61.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $61.425 to $61.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. Stock Option is fully vested and exercisable.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR